Research programme: T cell receptor cancer therapeutics - Kite Pharma/Leiden University Medical Center
Latest Information Update: 13 May 2016
At a glance
- Originator Kite Pharma; Leiden University Medical Center
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Cell replacements; T-cell receptor gene modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours